Absin Kit Powers mEVs-SKAP2 Therapy for Asthenoteratozoospermia

Against the backdrop of globally rising infertility rates, asthenoteratozoospermia—characterized by impaired sperm motility and abnormal morphology—has emerged as a leading etiology of male infertility, imposing a heavy burden on affected couples and representing a critical diagnostic and therapeutic bottleneck in reproductive medicine. A breakthrough study recently published in Signal Transduction and Targeted Therapy (2025, 10:416) unveiled the pivotal regulatory role of the hnRNPR–SKAP2 axis during spermatogenesis and developed an exosome-based SKAP2-targeted therapeutic strategy, offering a novel direction for asthenoteratozoospermia treatment. absin biochemical assay kits provided essential support throughout the investigation, enabling the research team to overcome technical hurdles.

I. Research Rationale: A Stepwise Decoding of the Core Defects Underlying Sperm Abnormalities

The team adopted a closed-loop framework of “clinical challenge → mechanistic dissection → therapeutic development”:

• Pathogenic culprit identification: To address the clinical dilemma of “unknown etiology and lack of therapy,” 572 asthenoteratozoospermia patients were enrolled. Whole-exome sequencing identified pathogenic HNRNPR mutations directly linked to human male infertility.
• Animal-model validation: Hnrnpr knock-in (KI) and germ-cell-specific conditional knockout (cKO) mice were generated, faithfully recapitulating the human phenotype and confirming the indispensable role of hnRNPR during spermatogenesis.
• Molecular-mechanism elucidation: Integrating scRNA-seq, proteomics, and RIP-seq revealed a “mutation → splicing aberration → functional defect” axis: hnRNPR, in an m⁶A-dependent manner, regulates alternative splicing of Skap2 pre-mRNA, thereby controlling cytoskeletal remodeling and mitochondrial alignment in spermatids.
• Targeted-therapy development: To overcome the difficulty of restoring sperm function, milk-derived exosomes (mEVs) were engineered to carry SKAP2 protein; both in-vivo injection and in-vitro co-culture validated therapeutic efficacy, providing a clinically translatable regimen.

II. Key Findings: Three Breakthroughs Tackling the Asthenoteratozoospermia Conundrum

1. Novel Pathogenic Gene Identified

HNRNPR mutations were formally established as a significant genetic cause of asthenoteratozoospermia. Mutations precipitate acrosome loss and neck-structure disorganization, leading to markedly reduced progressive motility (Fig. 1i–j).

2. Regulatory Mechanism Deciphered

The hnRNPR–SKAP2 axis was revealed as a central coordinator: hnRNPR acts as an m⁶A-dependent splicing mediator that directly binds m⁶A-modified sites within Skap2 mRNA, ensuring correct splicing and thereby maintaining F-actin assembly and microtubule stability—offering a critical molecular target for intervention (Fig. 5).

3. Innovative Therapeutic Strategy Developed

An mEVs-SKAP2 delivery system was successfully constructed. In vivo administration significantly improved sperm motility (Fig. 7c–d) and reduced morphological defects in KI mice (Fig. 7e), whereas in-vitro co-culture enhanced total and progressive motility of human asthenoteratozoospermic sperm (Fig. 9b–c) and restored disorganized mitochondrial alignment (Fig. 8), breaking the deadlock of limited therapeutic efficacy.

III. Powered by absin: Critical Reagents Supporting the Full Research Pipeline

In this clinically oriented, high-impact study, absin’s Bradford Protein Assay Kit (Cat. #abs580304) served as the core tool for accurate protein quantification, ensuring data reliability and precision for therapeutic development.

Product Information & Application Scenario

Product	Catalog #	Application
Bradford Protein Assay Kit	abs580304	Precise quantification of SKAP2 loaded into exosomes, ensuring accurate dosing in therapeutic interventions and reliable efficacy validation

Key Roles in the Study

• Standardization of the therapeutic system: After electroporating SKAP2 into milk-derived exosomes to generate mEVs-SKAP2, the Bradford kit enabled accurate SKAP2 quantification, guaranteeing uniform dosing across in-vivo and in-vitro assays, eliminating concentration-derived experimental bias, and ensuring reproducibility.
• Deep validation of therapeutic mechanism: The kit provided normalized protein loading for Western blot analyses, securing reliable quantification of F-actin, SKAP2, and other key proteins (Fig. 4k), thereby substantiating the conclusion that “mEVs-SKAP2 improves sperm function via cytoskeletal repair” and clarifying the therapeutic pathway.

IV. Implications & Future Perspectives

This study not only deciphers the molecular pathogenesis of asthenoteratozoospermia but also develops a clinically translatable targeted therapy, providing a brand-new solution to the long-standing clinical challenge of poor sperm quality and limited therapeutic options.

As a dependable partner in research, absin continuously empowers life-science investigations with high-quality reagents, offering solid support for technical breakthroughs in reproductive medicine, molecular biology, and beyond. With ongoing advances in exosome-delivery technology, mEVs-SKAP2 is poised to become a novel biological agent for asthenoteratozoospermia, while absin will remain dedicated to developing premium bio-reagents, supplying core tools for more clinically focused projects and jointly promoting progress in reproductive health!

Cat. #	Product	Size
abs580304	Bradford Protein Quantification Kit	1000T/2500T

Contact Absin

Absin provides antibodies, proteins, ELISA kits, cell culture, detection kits, and other research reagents. If you have any product needs, please contact us.

Absin Bioscience Inc. worldwide@absin.cn

Follow us on Facebook: Absin Bio